News
21h
Zacks Investment Research on MSNAmgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...
A federal district court in Delaware ruled that Viatris’ product, currently awaiting approval from the US Food and Drug Administration (FDA), does not infringe on Novo Nordisk’s patent for the ...
Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...
Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Novo Nordisk A/S (NYSE:NVO) is one of the stocks that Jim Cramer shed light on. A caller asked about the stock’s status, and ...
The Danish government and the foundation behind Novo Nordisk A/S will invest €80 million ($93 million) in a Microsoft-powered ...
22h
Zacks Investment Research on MSNHere's Why Novo Nordisk (NVO) is a Strong Value StockFor new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers’ ...
The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...
Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...
Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results